Transdermal Formulation, Development, and Manufacturing

We’re transforming transdermal delivery systems. By developing or in-licensing transdermal patches in a variety of therapeutic categories, our development portfolio includes pain management, cardiovascular, and neurologic care.

What We Do

ProSolus, Inc. delivers sophisticated transdermal solutions customized to meet your needs and exceed your expectations. We formulate, develop, and manufacture high-barrier-to-entry transdermal drug delivery products in our state-of-the-art laboratories and manufacturing facility. Our patches are designed with the patient in mind.

How We Do It

Our research and development team works collaboratively with our suppliers to create polymers and design combinations of excipients that improve the absorption of medications through the skin without having to resort to exotic permeation enhancers. Focused on what lies ahead, our team continues to explore methods to optimize transdermal drug delivery.


ProSolus is an experienced partner with unrivaled transdermal prowess. Our experts are committed to delivering a customized experience every step of the way concept through completion. Whether you need formulation, development, and/or manufacturing support, we’ll provide sophisticated solutions tailored to your needs.

About ProSolus, Inc.

ProSolus, Inc. is a wholly owned subsidiary of Canoa, Inc.  We are focused on formulating and developing high-barrier-to-entry Transdermal Drug Delivery systems (TDDs) for ANDA, NDA, and 505(b)(2) applications.

Our state-of-the art pharma facility in Miami, Florida is managed by a seasoned leadership team with more than 65 years of experience. With the newly completed manufacturing wing and 50 million+ transdermal patch capacity, ProSolus effectively and efficiently delivers results from the conceptual formulation stage, through the clinical stage, to the coating stage completing the cycle and preparing the product for packaging.

Recent News

Canoa Inc. to Acquire Privately-Held ProSolus Inc.

Canoa Inc. to Acquire Privately-Held ProSolus Inc., Accelerating Transdermal Patch Drug Delivery Product Development MIAMI, Florida, August 02, 2019 – Canoa Inc. (“Canoa”), a Delaware corporation with a focus on healthcare and pharmaceuticals, today announced that it has agreed to acquire ProSolus® Inc. (“ProSolus”), from Mission Pharmacal® Company, in an all-cash transaction. ProSolus is a…

ProSolus Seeks Higher Utilization of Transdermal Drug Delivery Technology

ProSolus Seeks Higher Utilization of Transdermal Drug Delivery TechnologyParent company, Mission Pharmacal, expands commitment to patch technology with significant investments in manufacturing and commercial team. MIAMI, Fla. (April 25, 2017) – ProSolus, Inc. (“ProSolus”) is doubling down on its efforts to expand the utilization of transdermal drug delivery technologies. Today Mission Pharmacal Company (“Mission”) and…

Juan Mantelle featured in PharmaVOICE 100 issue

We’re excited to share that Juan Mantelle, COO of ProSolus, Inc., is featured in the 2016 PharmaVOICE 100 issue, in the Commanders & Chiefs section. Congratulations Juan! The PharmaVoice 100 is a list of inspirational leaders, representing a wide range of industry sectors and functional areas, who are having an extraordinary and positive impact on…